Changes in plasma endothelin-1 levels reflect clinical response to β- blockade in chronic heart failure

American Heart Journal

Volumn 131, Issue 2, 1996, Pages 337-341

  Krum, Henry ^a,c   Gu, Anguo ^a   Wilshire Clement, Michelle ^b   Sackner Bernstein, Jonathon ^a   Goldsmith, Rochelle ^a   Medina, Norma ^a   Yushak, Madeline ^a   Miller, Myron ^b   Packer, Milton ^a  

^a The New York Presbyterian Hospital   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; ENDOTHELIN 1; PLACEBO;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEART STROKE VOLUME; HORMONE RESPONSE; HUMAN; LUNG WEDGE PRESSURE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030023824     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90363-4     Document Type: Article

References (15)

1. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 1992;85:1374-9.
2. Rodehoffer RJ, Lerman A, Heublin DM, Burnett JC. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992;67:719-24.
3. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M. Importance of endothelin in the exercise intolerance of heart failure. Am J Cardiol 1995;75:1282-3.
4. Tsutamato T, Kanamori T, Kinoshita M. Plasma endothelin-1 concentration as a prognostic predictor in patients with heart failure. Circulation 1991;84:II-470.
5. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.
6. Krum H, Schwartz B, Sackner-Bernstein J, Penn J, Goldsmith RL, Kukin M, Medina N, Yushak M, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe heart failure. Circulation 1995;92:1499-506.
7. Davenport AP, Ashby MJ, Easton P, Ella S, Bedford J, Dickerson C, Nunez DJ, Capper SJ, Brown MJ. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci 1990;78:261-4.
8. Goodfriend TL, Ball DL. Angiotensin and reuin. In: Abraham GE, ed. Angiotensin and renin. New York: Marcel Dekker, 1977:511-3.
9. Davis GC, Kissinger PT, Shoup RE. Strategies for determination of serum or plasma norepinephrine by reverse phase liquid chromatography. Anal Chem 1981;53:156-9.
10. Underwood D, Aarhus L, Heublin D, Burnett JC. Endothelin in thoracic inferior vena caval constriction. Am J Physiol 1992;263:H951-5.
11. Dohi Y, Hahn AWA, Boulanger CM, Buhler FR, Luscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992;19:131-7.
12. Kramer BK, Nishida M, Kelly RA, Smith TW. Endothelins. Myocardial actions of a new class of cytokines. Circulation 1992;85:350-4.
13. Dubin D, Pratt RE, Dzau VJ. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vase Med Biol 1989;1:150-4.
14. Cohn JN, Levine TB, Olivari MT. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
15. Lee WH, Packer M. Prognostic importance of serum sodium concentrations and its modification by converting-enzyme inhibition in patients with severe heart failure. Circulation 1986;73:257-67.